What question did this study set out to answer?

To describe clinical characteristics and treatment patterns in recently diagnosed high-risk patients with ER+/HER2- early-stage breast cancer.

February 19, 2026Clinical Cancer Research

Abstract PS3-09-05: Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC)

View Full Paper

Ask AI

Bookmark

To describe clinical characteristics and treatment patterns in recently diagnosed high-risk patients with ER+/HER2- early-stage breast cancer.
Observational, retrospective cohort study
Used electronic health records from five oncology centers in the UK and France
Included patients diagnosed between 2020 and 2024
Assessed treatment patterns such as surgery, chemotherapy, and radiotherapy
Included 421 patients, with a majority being lymph node positive (88%)
85% were found to be ER-positive (≥10% expression)
Treatment included 98% undergoing surgery, with most receiving adjuvant chemotherapy (48%) and radiotherapy (72%)
Notable increase in adjuvant abemaciclib use from 5% in 2020 to 47% in 2023

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Observational cohort study examines treatment patterns in high-risk early-stage ER+/HER2- breast cancer patients, suggesting trends in clinical practice.

Cite This Study

Cottu et al. (2026) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f035a https://doi.org/10.1158/1557-3265.sabcs25-ps3-09-05

View Full Paper

Ask AI

Bookmark

Implication

Observational cohort study examines treatment patterns in high-risk early-stage ER+/HER2- breast cancer patients, suggesting trends in clinical practice.

Abstract PS3-09-05: Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC)

Key Points

Discussion

Implication

Cite This Study

Abstract PS3-09-05: Real-world clinical characteristics and treatment patterns among UK and French patients with a recent diagnosis (2020 onwards) of early-stage, estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer (ER+/HER2-eBC)

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider